PRL and peripartum cardiomyopathy: Preliminary data supporting the use of bromocriptine to suppress prolactin release showed promise in the treatment of peripartum cardiomyopathy, but results from further clinical data were less clear.63,66,70,71 The ongoing Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy (REBIRTH) trial, expected to be completed by 2026, should provide more guidance regarding the role of bromocriptine therapy.